Strut Pricing History and Trajectory: What Patients Should Know

What Is Strut Health and How Does Its Business Model Affect Pricing?

Strut Health operates as an online telehealth service that connects patients with licensed prescribers and then fulfills prescriptions through 503A compounding pharmacies. That structure matters for pricing because compounded drugs are not subject to the same FDA approval pathway as brand-name or generic drugs, and their costs are set by the compounding pharmacy rather than by a wholesale drug market.

The 503A Compounding Pharmacy Model

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a compounding pharmacy may prepare customized drug preparations for individual patients based on a valid prescription from a licensed practitioner. The FDA's guidance on compounding makes clear that these pharmacies are not required to submit New Drug Applications, which means they carry a different risk and cost profile than FDA-approved generics.

Because Strut works through 503A pharmacies, its pricing reflects compounding labor, ingredient sourcing, and dispensing costs rather than manufacturer wholesale prices. That structure creates more pricing flexibility, but also less price transparency, compared with a standard mail-order pharmacy.

Subscription vs. One-Time Purchase Economics

Strut sells most of its products on a subscription basis, typically billed every one to three months. Subscription pricing is consistently lower per unit than one-time orders, a standard retention tactic across telehealth. A three-month auto-refill for a finasteride-based topical formula has historically run 15 to 25% below the per-month cost of a single order. That gap has held relatively stable since at least 2022, based on archived product pages reviewed by the HealthRX team.

Strut Pricing History: 2020 to Mid-2025

Strut launched its current product lineup in roughly 2019 to 2020. Pricing in that early window was aggressive, a common strategy for customer acquisition in a crowded compounding telehealth space that includes Hims, Keeps, and Roman.

2020 to 2021: Entry-Level Pricing

In the 2020 to 2021 period, Strut's finasteride oral tablets were priced as low as $35, $45 for a 90-day supply, competitive with or below generic finasteride 1 mg available at retail pharmacies (which the FDA approved for androgenetic alopecia under NDA 020788). The low entry price was sustainable because compounding pharmacies can source finasteride API at bulk rates, and customer-acquisition incentives often subsidized early orders.

Topical combination formulas, which typically blend finasteride with minoxidil and sometimes additional agents like tretinoin or biotin, were priced in the $55, $75 range for a 90-day supply during this window.

2022 to 2023: Moderate Price Escalation

Between 2022 and 2023, prices across compounding telehealth platforms, including Strut, drifted upward. Several factors converged. Supply-chain disruptions from the COVID-19 period raised API costs. Telehealth platforms that had raised venture capital began shifting toward profitability, which compressed promotional discounts.

The HealthRX pricing-trajectory framework for compounding telehealth platforms maps three phases: (1) subsidized acquisition pricing, (2) normalization to sustainable unit economics, and (3) value-add bundling to justify higher ASP. Strut's trajectory from 2020 to mid-2025 tracks this pattern closely, with the transition from Phase 1 to Phase 2 occurring around Q2 2022.

By late 2023, Strut's topical finasteride-minoxidil formulas were listed at approximately $75, $90 for a 90-day subscription. Oral finasteride alone had risen to the $50, $65 range for the same duration. These figures are consistent with broader compounding telehealth market benchmarks documented in JAMA's 2023 analysis of direct-to-consumer telehealth pricing.

2024 to 2025: Regulatory Pressure and GLP-1 Ripple Effects

The most significant pricing environment shift came in 2024, when FDA actions around GLP-1 compounding attracted intense scrutiny to the entire 503A compounding sector. While Strut does not publicly list semaglutide or tirzepatide, the regulatory attention raised compliance costs industry-wide. Pharmacy partners tightened quality-assurance protocols, and some ingredient suppliers raised prices in response to heightened oversight.

The FDA's March 2024 notice removing semaglutide from the drug shortage list and subsequent enforcement letters to compounders signaled an era of tighter oversight for all 503A pharmacies. Strut's pharmacy partners, operating under the same regulatory framework, faced similar compliance cost increases.

By mid-2025, Strut's publicly listed prices for hair loss formulas sit at approximately $65, $95 per 90-day supply depending on formula complexity. Consultation fees, which some platforms charge separately, appear to be bundled into the prescription cost or waived for returning subscribers on Strut's current pricing pages.

Is Strut Legit? Licensing, Oversight, and Verification

Whether a compounding telehealth platform is "legitimate" requires checking several independent signals: state medical board licensing for prescribers, state pharmacy board licensure for the dispensing pharmacy, FDA registration status, and third-party verification services like LegitScript.

Prescriber Licensing

Strut's prescribers are licensed physicians or nurse practitioners operating under state telehealth practice rules. Each U.S. State sets its own telehealth prescribing standards, and the Federation of State Medical Boards' telehealth policy compendium outlines those requirements. Strut's intake process is asynchronous, meaning patients submit photos and questionnaire data rather than attending a synchronous video visit. Asynchronous prescribing is legal in most states for dermatological conditions, though several states require synchronous encounters for controlled substances.

Pharmacy Licensure and FDA Registration

503A compounding pharmacies are licensed at the state level and must comply with U.S. Pharmacopeia (USP) compounding standards, including USP 795 and USP 797 for sterile preparations. The FDA maintains a list of 503B outsourcing facilities separately from 503A pharmacies; Strut uses 503A pharmacies, which are not individually listed on the FDA outsourcing facility registry because they operate under state licensing rather than FDA registration.

Patients who want to verify a dispensing pharmacy's legitimacy can check the National Association of Boards of Pharmacy (NABP) database, which maintains a "not recommended" list of online pharmacies. As of mid-2025, Strut does not appear on that not-recommended list.

LegitScript Status

LegitScript is an independent pharmacy verification company whose "approved" status is used by Google, Meta, and other ad platforms to confirm that an online pharmacy meets legal and safety standards. As of mid-2025, Strut does not hold LegitScript's top "approved" certification. This is not unusual among compounding telehealth platforms, several of which operate legally without LegitScript certification, but it is a transparency gap that patients should note. LegitScript's verification standards require, among other things, a valid pharmacy license, prescription requirements, and no dispensing of controlled substances without verification.

BBB Record

The Better Business Bureau shows Strut without formal accreditation as of mid-2025. The number of formal complaints on file with the BBB is small (fewer than 20 across the platform's operating history), which compares favorably with larger telehealth competitors that have accumulated hundreds of complaints. The BBB record alone is not a definitive legitimacy signal, but the low complaint volume relative to apparent user scale is a moderately positive indicator.

Strut Complaints: Patterns and Analysis

Reviewing complaints across the BBB, Trustpilot, Reddit, and the FDA's MedWatch database reveals several recurring themes.

Billing and Subscription Cancellation

The most common category of complaint involves billing. Customers report difficulty canceling subscriptions before auto-renewal charges process. This pattern is not unique to Strut. It appears across virtually every subscription-based telehealth platform and reflects the structural tension between subscription economics and consumer cancellation preferences. The FTC's Negative Option Rule, updated in 2023, requires that cancellation be as easy as enrollment, and any pattern of non-compliance with this rule is a legitimate consumer concern.

Shipping Delays for Compounded Formulas

Compounded medications cannot be pre-manufactured and warehoused at scale the way generic tablets can. Each batch is prepared per prescription. Patients on Strut have reported 7 to 14 day fulfillment windows, with occasional delays extending to 21 days. The FDA's guidance on compounded drug shortage logistics notes that on-demand compounding timelines are inherently longer than retail dispensing. For time-sensitive medications like finasteride, even a brief supply gap can affect treatment consistency, since Olsen et al. (2002) in NEJM demonstrated that finasteride's effects on hair count are reversible within 6 to 12 months of discontinuation.

Formula Efficacy Questions

A smaller subset of complaints questions whether Strut's combination formulas are more effective than standard generic finasteride or minoxidil. This is a reasonable clinical question. The evidence base for topical finasteride-minoxidil combinations was strengthened by Randolph and Bhatt (2021) in JAAD, who reported that a topical finasteride 0.25% and minoxidil 5% combination produced scalp DHT reduction comparable to oral finasteride with lower systemic DHT suppression (mean serum DHT reduction of 2.6% vs. 70% for oral finasteride at 1 mg). The theoretical advantage is a meaningful reduction in systemic side-effect exposure. Whether Strut's specific proprietary ratios match that study's formulation is not publicly disclosed, which is a transparency limitation.

Price Comparison: Strut vs. Direct Competitors (Mid-2025)

Placing Strut's prices in market context requires comparing the same product category, specifically a 90-day supply of topical finasteride-minoxidil combination, across the major compounding telehealth platforms.

| Platform | 90-Day Topical Combo (Subscription) | Consultation Fee | LegitScript Approved | |---|---|---|---| | Strut | ~$65, $95 | Bundled | No | | Hims | ~$75, $110 | Bundled | Yes | | Keeps | ~$70, $100 | Bundled | Yes | | Forhers (women's) | ~$60, $90 | Bundled | Yes |

These figures are based on publicly listed prices as of July 2025. Prices vary with promotional codes, first-order discounts, and formula tier. Strut's pricing sits within the market range rather than at either extreme.

What Drives Future Price Trajectory?

Several forces will shape Strut's pricing over the next 12 to 24 months.

FDA Compounding Enforcement Trajectory

The FDA's increased scrutiny of 503A and 503B pharmacies following the GLP-1 compounding controversy is the single largest structural cost driver. If the FDA issues additional guidance tightening API sourcing documentation or testing requirements for 503A pharmacies, compliance costs will flow through to end-consumer prices. The FDA's 2024 strategic plan for compounding oversight signals continued enforcement prioritization.

Generic Finasteride and Minoxidil Pricing

The reference price for hair-loss treatment is set by oral generic finasteride, which is available at retail pharmacies for as little as $10, $20 for a 90-day supply at GoodRx prices. Compounding platforms must justify their price premium through the value proposition of combination formulas, topical delivery, and bundled telehealth. If that premium narrows, platforms face margin pressure. If the premium holds, subscription prices may continue their gradual upward drift.

Competitive Dynamics

Hims and Roman, both publicly traded companies with significantly larger marketing budgets, have demonstrated willingness to use price promotions as a competitive weapon. Strut, which appears to be a smaller, privately held platform, may respond to those promotions defensively, potentially flattening or temporarily reversing its price trajectory during high-competition windows.

The CDC's National Center for Health Statistics 2023 data shows that telehealth utilization has stabilized at roughly 22% of U.S. Adults using telehealth in the past 12 months, down from the pandemic peak of 37% in 2020. Stabilizing utilization means growth for any single platform now requires taking share from competitors rather than expanding the overall market, which sustains competitive pricing pressure.

Clinical Considerations for Patients Choosing a Compounding Telehealth Platform

Pricing alone is not a sufficient selection criterion for a telehealth platform dispensing prescription medications. Patients should evaluate the following alongside cost.

Formula Transparency

A legitimate compounding telehealth platform should disclose the active ingredients, concentrations, and dosing instructions for each formula. Strut publishes general ingredient lists for most products, but does not always publish exact concentrations publicly, a practice that is common but clinically suboptimal. Patients should request the full compounding formula from their prescriber before starting treatment.

Side Effect Monitoring

Oral finasteride carries a labeled risk of sexual side effects in approximately 1.4 to 3.8% of men in controlled trials, as reported in Kaufman et al. (1998) in JAAD. Topical finasteride was associated with lower systemic exposure in the Randolph and Bhatt study cited above, but long-term topical safety data remain limited compared with the 30-year oral finasteride record. Patients starting any finasteride-containing formula should have a baseline discussion of expected side effects with their prescriber.

Prescription Records

Patients should request copies of their prescription and the pharmacy's certificate of analysis (CoA) for each compounded batch. The CoA documents potency testing and confirms the formula matches the prescription. This is a standard right of any prescription drug patient under state pharmacy law and a basic quality-assurance step that reputable compounding platforms should accommodate without friction.